The Drake Institute now offers remote treatment for ADHD, autism, and other brain-based disorders. With the help of our trained clinicians, you can get the help you need from the comfort of your home.
Learn More >>ADHD combined type is sometimes used to describe ADHD Combined Presentation, which is one of the three primary types of ADHD. The others are ADHD Predominantly Hyperactive-Impulsive Presentation, and ADHD Predominantly Inattentive Presentation.[i]
Combination type ADHD is, as the name suggests, a combination of all three primary characteristics of ADHD. It is the most common form of ADHD, being twice as common as the inattentive presentation and around eight times more common than the hyperactive-impulsive presentation.[ii]
For decades, the Drake Institute has used advanced treatment technologies to create customized treatment protocols for patients with ADHD and other brain-based conditions. Brain map-guided neurofeedback and neurostimulation help our ADHD patients reduce their symptoms and lead better lives.
For more information about how the Drake Institute treats ADHD and several other brain-based disorders, please fill out the consultation form or call us at 800-700-4233.
What is ADHD combined type, and what does it look like?
Because this subtype of ADHD is represented by a combination of hyperactivity, impulsivity, and inattention, signs of combined ADHD will include symptoms from the other subtypes.[iii] For example, a person with ADHD combined type may experience difficulties focusing as well as difficulty controlling hyperactivity and impulsive behaviors.
ADHD predominantly combined type has specific diagnostic requirements.[iv] To be diagnosed with the combination type ADHD, an individual must exhibit at least 6 of the 9 symptoms listed for each of the two categories, inattentive and hyperactive-impulsive. For those age 17 and older, only 5 of 9 symptoms are required to receive a diagnosis.
The specific symptoms for each presentation are below:
All types of ADHD may present in different degrees of severity, characterized as mild, moderate, and severe. Indicating this level is now a requirement for diagnosis as defined by the DSM-5. The severity levels indicate how much difficulty the symptoms cause in social, work, or school settings and may change over time.[v]
As described by CHADD: “Few symptoms beyond the required number for diagnosis are present, and symptoms result in minor impairment in social, school or work settings.”
Symptoms or functional impairment are between mild and severe.
More symptoms than the required diagnostic number are present, with one or more symptoms being particularly severe. Symptoms of this severity level result in marked impairment in social, school, or work settings.
ADHD is diagnosed by clinicians according to criteria in the DSM-5. For children up to age 16 to receive a diagnosis, they must exhibit six or more of the listed symptoms for at least six months. For individuals 17 and older, at least 5 of the symptoms must be present.[vi]
The symptoms are divided into two categories: inattention and hyperactivity/impulsivity. If enough of the criteria are met in both categories, a person will be diagnosed with ADHD combined type, or more formally known as ADHD combined presentation.
Symptoms and signs of combined ADHD are typically caused by an underlying dysregulation of the brain.
ADHD is a lifelong diagnosis for many, but some individuals may outgrow the disorder. Symptoms may change over time, especially as adulthood is reached.[vii]
At the Drake Institute, we’ve had some patients who by the completion of their treatment program no longer meet the criteria for ADHD.
Over the last 40 years, the Drake Institute has clinically pioneered the use of advanced treatment technologies to treat a variety of brain-based medical disorders such as ADHD, Autism Spectrum Disorder, PTSD, anxiety, panic disorder, depression, insomnia, and more. Using a combination of brain map-guided neurofeedback and sometimes neurostimulation, our Medical Director creates customized treatment protocols to address each patient's needs.
To develop our individualized treatment plans, we first complete a qEEG brain map analysis for each patient. Brain mapping helps us identify which specific regions or networks of the brain are dysregulated linked to symptoms.
To collect this data, 19 sensors are placed around the scalp in areas of the brain responsible for language, focus, memory, executive functioning, social/emotional understanding and behavioral/emotional regulation. The 19 sensors measure and record brainwave activity that is processed through a normative database of neurotypical individuals.
When we compare the patient's results with those of neurotypical individuals, we can identify regions or networks of the brain that are dysregulated and causing symptoms. This information also allows us to determine how these areas are dysregulated so that we can develop specific treatment protocols that help improve brain functioning and reduce symptoms.
During neurofeedback training/treatment, sensors are once again placed on the scalp. The sensors record and display instantaneous brainwave activity visually in real-time on a computer screen with simultaneous auditory feedback as well.
During neurofeedback sessions, the patient is seeing the results of how their brain is working and with this information, they learn to improve their brainwave activity by guiding it toward healthier, more appropriately functional brainwave patterns.
We do not administer any drugs or perform invasive procedures during this process. Instead, the patient is improving their own brain functioning, guided by visual and auditory feedback.
As an adjunct to neurofeedback, we may also use neurostimulation guided by qEEG brain map findings to gently stimulate the brain into healthier functional patterns. In our experience, some patients may benefit even more from neurofeedback if we also use neurostimulation. We have found this particularly helpful for lower-functioning children on the Autism Spectrum.
In the last forty years, Drake has helped thousands of patients with various disorders such as autism, ADHD, PTSD, anxiety, panic disorder, depression, insomnia, migraine headaches, irritable bowel syndrome, and hypertension reduce or resolve their symptoms and thereby achieve a better quality of life. Call us at 1-800-700-4233 or fill out the free consultation form to get started.
[i] https://www.hopkinsmedicine.org/health/conditions-and-diseases/adhdadd
[ii] https://add.org/adhd-combined-type/
[iii] https://psychcentral.com/adhd/adhd-combined-type
[iv] https://www.ncbi.nlm.nih.gov/books/NBK519712/table/ch3.t3/
[v] https://chadd.org/about-adhd/overview/
“David F. Velkoff, M.D., our Medical Director and co-founder, supervises all evaluation procedures and treatment programs. He is recognized as a physician pioneer in using biofeedback, qEEG brain mapping, neurofeedback, and neuromodulation in the treatment of ADHD, Autism Spectrum Disorders, and stress related illnesses including anxiety, depression, insomnia, and high blood pressure. Dr. David Velkoff earned his Master’s degree in Psychology from the California State University at Los Angeles in 1975, and his Doctor of Medicine degree from Emory University School of Medicine in Atlanta in 1976. This was followed by Dr. Velkoff completing his internship in Obstetrics and Gynecology with an elective in Neurology at the University of California Medical Center in Irvine. He then shifted his specialty to Neurophysical Medicine and received his initial training in biofeedback/neurofeedback in Neurophysical Medicine from the leading doctors in the world in biofeedback at the renown Menninger Clinic in Topeka, Kansas. In 1980, he co-founded the Drake Institute of Neurophysical Medicine. Seeking to better understand the link between illness and the mind, Dr. Velkoff served as the clinical director of an international research study on psychoneuroimmunology with the UCLA School of Medicine, Department of Microbiology and Immunology, and the Pasteur Institute in Paris. This was a follow-up study to an earlier clinical collaborative effort with UCLA School of Medicine demonstrating how the Drake Institute's stress treatment resulted in improved immune functioning of natural killer cell activity. Dr. Velkoff served as one of the founding associate editors of the scientific publication, Journal of Neurotherapy. He has been an invited guest lecturer at Los Angeles Children's Hospital, UCLA, Cedars Sinai Medical Center-Thalians Mental Health Center, St. John's Hospital in Santa Monica, California, and CHADD. He has been a medical consultant in Neurophysical Medicine to CNN, National Geographic Channel, Discovery Channel, Univision, and PBS.”